This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Scientists Rank Genzyme Among Best Employers

Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), announced today that scientists have named the company one of the most highly regarded employers in the biopharmaceutical industry. In a survey commissioned by Science and the American Association for the Advancement of Science, Genzyme ranked among 20 companies in the industry with the best reputations as employers. Genzyme was recognized in particular for valuing and respecting its scientists, for its social responsibility, and for doing important, quality research.

This is the 10th consecutive year that Genzyme has earned this distinction.

“We continue to foster an environment of interconnectivity within our R&D organization, in which all employees have a shared focus on discovering and developing medicines to make a difference in patients’ lives,” said Rich Gregory, Senior Vice President and Head of the Sanofi-Genzyme R&D Center.

More than 4,000 Science readers globally participated in the survey. Fifty-six percent of respondents work in biotechnology and 35 percent for a pharmaceutical company. Twenty-three percent of respondents reported working in basic research, 30 percent in applied research, and 30 percent in development. Seventy-eight percent of respondents were based in North America, 14 percent in Europe, and 5 percent in the Asia/Pacific Rim.

About Genzyme, a Sanofi Company

Genzyme has pioneered the development and delivery of transformative therapies for patients affected by rare and debilitating diseases for over 30 years. We accomplish our goals through world-class research and with the compassion and commitment of our employees. With a focus on rare diseases and multiple sclerosis, we are dedicated to making a positive impact on the lives of the patients and families we serve. That goal guides and inspires us every day. Genzyme’s portfolio of transformative therapies, which are marketed in countries around the world, represents groundbreaking and life-saving advances in medicine. As a Sanofi company, Genzyme benefits from the reach and resources of one of the world’s largest pharmaceutical companies, with a shared commitment to improving the lives of patients. Learn more at

About Sanofi

Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,832.63 +112.71 0.64%
S&P 500 2,092.35 +11.94 0.57%
NASDAQ 5,133.9850 +25.3190 0.50%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs